Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NRXP |
---|---|---|
09:32 ET | 957 | 2.6 |
09:34 ET | 100 | 2.59 |
09:39 ET | 100 | 2.59 |
09:45 ET | 600 | 2.64 |
09:54 ET | 127 | 2.65 |
10:17 ET | 200 | 2.6504 |
10:19 ET | 100 | 2.67 |
10:21 ET | 240 | 2.6894 |
10:24 ET | 435 | 2.69 |
10:30 ET | 200 | 2.69 |
10:33 ET | 150 | 2.69 |
10:44 ET | 100 | 2.71 |
10:48 ET | 100 | 2.685 |
10:51 ET | 672 | 2.6999 |
10:53 ET | 2430 | 2.71 |
10:55 ET | 300 | 2.7 |
11:06 ET | 339 | 2.7369 |
11:13 ET | 100 | 2.73 |
11:18 ET | 339 | 2.73 |
11:22 ET | 100 | 2.68 |
11:33 ET | 150 | 2.7039 |
11:49 ET | 720 | 2.7 |
12:05 ET | 195 | 2.7 |
12:36 ET | 200 | 2.73 |
12:38 ET | 600 | 2.71 |
12:41 ET | 100 | 2.7 |
12:45 ET | 702 | 2.7 |
12:48 ET | 498 | 2.7195 |
12:56 ET | 810 | 2.71 |
01:01 ET | 200 | 2.73 |
01:24 ET | 614 | 2.71 |
01:46 ET | 267 | 2.73 |
01:50 ET | 3802 | 2.72 |
02:00 ET | 100 | 2.72 |
02:11 ET | 100 | 2.71 |
02:36 ET | 421 | 2.7 |
02:44 ET | 323 | 2.7 |
03:02 ET | 400 | 2.7 |
03:05 ET | 200 | 2.68 |
03:30 ET | 500 | 2.6618 |
03:32 ET | 666 | 2.7011 |
03:43 ET | 100 | 2.7 |
03:59 ET | 267 | 2.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
NRX Pharmaceuticals Inc | 28.6M | -1.3x | --- |
Lisata Therapeutics Inc | 28.4M | -1.4x | --- |
BioVie Inc | 29.0M | -0.5x | --- |
Enlivex Therapeutics Ltd | 29.1M | -0.9x | --- |
Carmell Corp | 29.4M | -0.8x | --- |
NKGen Biotech Inc | 29.6M | 0.0x | --- |
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $28.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-2.06 |
Book Value | $-0.14 |
P/E Ratio | -1.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.